Osivax has been forced to alter the strategy for its influenza vaccine after the shot failed a phase 2b study. France’s ...

When Fierce last caught up with OMass Therapeutics’ CEO Ros Deegan, it was hard not to be impressed by the company’s ambition ...

AstraZeneca is paying insitro $40 million upfront to find novel drug targets for liver and heart diseases using artificial ...

Lakefront Biotherapeutics—the new name for Belgium’s Galapagos Therapeutics—has found a buyer for its unwanted cell therapy ...

Verastem Oncology's decision to refocus its R&D efforts on its KRAS inhibitor appears to be paying off, at least based on ...

Looking to expand its oncology portfolio, Gilead Sciences has tapped Vir Biotechnology’s masked T-cell engager (TCE) tech in ...

Biomea Fusion has shared phase 1 data on its oral GLP-1 prospect, shedding light on a small molecule designed to balance ...

Agilent Technologies is buying up the digital pathology software company Proscia in an all-cash transaction valued at $240 ...

Verdiva Bio has scrapped a phase 2 trial of its once-weekly oral GLP-1 drug candidate VRB-101. | Verdiva Bio has scrapped a ...

Up to 1,217 GSK employees in Belgium are at risk of losing their jobs as the Big Pharma rolls out its global cost-saving ...

Zealand Pharma is paying Generate Biomedicines $30 million upfront to collaborate on multispecific drug candidates for ...

Stryker will funnel around $400 million (£300 million) in a “strategic” investment in CMR Surgical and its robot surgery tech ...